65.53
-0.19
(-0.29%)
May 24 - Close
NYSE
real-time data -
Disclaimer
Currency in USD
| Range | 64.89 - 66.16 |
| 52 week | 62.34 - 110.79 |
| Open | 65.72 |
| Vol / Avg. | 1.17M/1.93M |
| Mkt cap | 7.48B |
| P/E | 20.68 |
| Div/yield | - |
| EPS | 3.17 |
| Shares | 114.10M |
| Beta | 0.43 |
| Inst. own | 93% |
Events
Jul 22, 2013
Q2 2013 Edwards Lifesciences Earnings Release
Jun 11, 2013
Edwards Lifesciences at William Blair Growth Stock Conference
- 3:50PM EDT -
Jun 11, 2013
Edwards Lifesciences at Goldman Sachs Healthcare Conference
- 11:00AM EDT -
May 15, 2013
Edwards Lifesciences at Bank of America Merrill Lynch Health Care Conference
May 14, 2013
Edwards Lifesciences Annual Shareholder Meeting
Apr 23, 2013
Q1 2013 Edwards Lifesciences Earnings Conference Call
Apr 23, 2013
Q1 2013 Edwards Lifesciences Earnings Release
Feb 26, 2013
Edwards Lifesciences at RBC Capital Markets' Healthcare Conference
Feb 25, 2013
Edwards Lifesciences at Citi Global Healthcare Conference
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | 29.17% | 15.43% |
| Operating margin | 38.68% | 20.66% |
| EBITD margin | - | 23.87% |
| Return on average assets | 25.73% | 13.96% |
| Return on average equity | 37.85% | 20.81% |
| Employees | 8,200 | - |
| Carbon Disclosure Rating | - | - |
Address
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Edwards Lifesciences Corporation (Edwards Lifesciences) is focused on technologies that treat structural heart disease and critically ill patients. A pioneer in the development and commercialization of heart valve products, Edwards Lifesciences is the manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. The Company also provides hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The products and technologies provided by Edwards Lifesciences to treat advanced cardiovascular disease or critically ill patients are categorized into three main areas: Surgical Heart Valve Therapy, which combines surgical heart valves and Cardiac Surgery Systems; Transcatheter Heart Valves; and Critical Care, which includes Vascular. In October 2012, it acquired BMEYE B.V.
Officers and directors
| Michael A. Mussallem | Chairman of the Board, Chief Executive Officer | |
| Thomas M. Abate | Chief Financial Officer, Corporate Vice President | |
| Aimee S. Weisner | Corporate Vice President, General Counsel | |
| Christine Z. McCauley | Corporate Vice President - Human Resources | |
| Donald E. Bobo Jr. | Corporate Vice President - Heart Valve Therapy | |
| Bruce P. Garren | Corporate Vice President - Public Affairs and Special Counsel | |
| John H. Kehl Jr. | Corporate Vice President - Strategy and Corporate Development | |
| Paul C. Redmond | Corporate Vice President - Global Corporate Operations | |
| Carlyn D. Solomon | Corporate Vice President - Critical Care and Vascular | |
| Patrick B. Verguet | Corporate Vice President, Europe, Middle East and Africa |
